Given that CDKN2A silencing and CDK overexpression have been frequently observed in patients with HCC, CDK inhibitors appear to be an attractive strategy for HCC treatment (16, 39, 51, 52). The gene discussed is CDKN2A; the disease is hepatocellular carcinoma.